Introduction
with an imaging agent, thereby allowing direct monitoring of drug delivery to tumors. The size of fenestrations in the tumor endothelium allows nanoparticles to pass from the circulation into the tumor interstitium where they can access cancer cells. Furthermore, molecules may also become trapped in this interstitium, which is a phenomenon generally referred to as the enhanced permeability and retention effect (Saha et al. 2010) . Several types of nanoparticles, such as metal-, polymer-, and lipid-based nanoparticles, have been developed to deliver therapeutic agents, including chemotherapeutic agents, radionuclides, photosensitizers, and siRNA. Targeting ligands/moieties, such as peptides, antibodies, or antibody fragments, can be attached to nanoparticles to improve therapeutic efficacy (Hussain et al. 2013) . In an attempt to increase specificity, liposomes, which are spherical vesicles formed by lipid bilayers, have been conjugated to monoclonal antibodies or antibody fragments for specific delivery to target cells. Studies have shown that antibody-conjugated liposomes caused significant tumor cytotoxicity and growth inhibition compared with non-targeted liposomes, making them a promising tool for future treatment in oncology (Pastorino et al. 2003) .
Epidermal growth factor receptor (EGFR) is one of the four members of the epidermal growth factor receptor family. It plays an important role in the proliferation, apoptosis, dedifferentiation, angiogenesis, invasion, and metastasis of tumor cells. As reported by some studies, 40-80 % of non-small cell lung cancers (NSCLC) , 20-25 % of breast cancers (Capelan et al. 2013) , 35-40 % of colorectal cancers (Normanno et al. 2009 ), and 80-90 % of head and neck squamous cell carcinomas (HNSCC) (Ang et al. 2002) showed EGFR overexpression. Molecular imaging and targeted therapy against EGFR are significant areas in cancer research, and several monoclonal antibodies against EGFR are available. The most advanced clinical member of this drug class is cetuximab (IMC-C225 or Erbitux; ImClone Systems Inc., NY, USA/Merck KGaA, Darmstadt, Germany), which competitively inhibits binding to both EGFR and EGFRvIII; cetuximab is the first FDA-approved EGFR-specific mAb for the treatment of patients with EGFR-expressing metastatic colorectal and head/neck cancers (Giaccone 2005) . Anti-EGFR immunoliposomes have already been produced (Mamot et al. 2003) .
Radioiodine therapy for differentiated thyroid carcinoma has been used for numerous years. Radioiodine kills not only sodium iodide symporter-expressing cells but also adjacent tumor cells because of the cross-fire effect of radiation therapy. In this paper, we describe the construction of 131 I-labeled anti-EGFR nanoparticles derived from cetuximab as a tumor-targeting vehicle for radionuclide therapy. These nanoparticles were characterized for cellular uptake, cytotoxicity, targeted cell killing with 131 I, and time-dependent cellular uptake of 131 I in breast cancer, colorectal cancer, NSCLC, and HNSCC cells in vitro; we also performed a radioiodine therapy study in NCI-H1972 NSCLC xenograft nude mice by intratumoral injection of nanoparticles in vivo.
Materials and methods

Materials
Reagents were obtained from the following sources: Dulbecco's modified Eagle's medium (DMEM) (Gibco), Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco), Minimum Essential Medium Eagles with Earle's Balanced Salts (MEM-EBSS) (Gibco), fetal bovine serum (FBS) (Gibco), rabbit polyclonal antihuman epidermal growth factor receptor antibody (Abcam, ab2430), and 5 mg/mL monoclonal antibody (MERCK Inc., C225, cetuximab).
Cell lines
The NSCLC cell lines NCI-H292 and NCI-H1975; breast cancer cell lines MDA-MB-231, MDA-MB-453, and MDA-MB-468; colorectal cancer cell line LS180; and squamous cell carcinoma cell line A431 were purchased from Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/Peking Union Medical College (Beijing, China); EGFR was overexpressed in all of these cell lines (Mamot et al. 2003 (Mamot et al. , 2006 Nagaria et al. 2013; Zhou et al. 2012) . The cell lines MDA-MB-231, MDA-MB-453, MDA-MB-468, and A431 were cultured in DMEM supplemented with 10 % FBS and 1 % penicillin/streptomycin. The cell lines NCI-H292 and NCI-H1975 were cultured in RPMI 1640 medium supplemented with 10 % FBS and 1 % penicillin/streptomycin. The cell line LS180 was cultured in MEM-EBSS medium supplemented with 10 % FBS and 1 % penicillin/streptomycin. The cell cultures were stored in a humidified atmosphere containing 5 % CO 2 buffered with ambient air at 37 °C.
Preparation, conjugation, and characterization of nanoparticles (Liu et al. 2014)
The amphiphilic BSA-PCL conjugate was synthesized as previously described (Liu et al. 2014) , and the nanosized self-assembled amphiphilic BSA-PCL conjugate was obtained via the emulsion-solvent evaporation method (Du et al. 2013) . Briefly, 4 mg of BSA-PCL conjugate was dissolved in 4 mL of phosphate buffer (PB, 0.1 M, pH 7.4) at room temperature and activated with N-(3-dimethyl amino propyl)-3-2 ethyl carbon imine hydrochloride (EDC) and N-hydroxy succinimide (NHS) for 15 min, to which 5 mg/ mL cetuximab antibodies were added (100 μg cetuximab antibodies per 1 mg BSA-PCL) at 4 °C overnight. The obtained PB solutions of the self-assemblies of the BSA-PCL conjugate and the cetuximab-decorated BSA-PCL conjugate EGFR-BSA-PCL were stored at 4 °C. The EGFR-BSA-PCL and BSA-PCL conjugates were synthesized by Liu Zhongyun, Ph.D., and Professor Chang Jin from TianJin University, Department of Polymer Materials Science and Engineering (Liu et al. 2014) . Nanoparticles were dissolved in 10 % Triton X-100 for measurement of BSA and cetuximab antibody content by high-performance liquid chromatography (HPLC) (Chen et al. 2015) . Measurement of the amount of antibody per nanoparticle was performed by the ratio of their surface areas; the BSA and EGFR protein qualification were performed by high-performance liquid chromatography (HPLC), and the detailed description is provided by in Kao et al. (2013) and Cho et al. (2010) . The cellular binding and uptake of two different nanoparticles, EGFR-BSA-PCL and BSA-PCL, were evaluated by confocal microscopy and flow cytometry in seven EGFRoverexpressing cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, and A431). The nanoparticles were added at a concentration of 1 mg/10 6 cells and incubated for 4 h at 37 °C. After incubation, the cells were washed three times with PBS, fixed with 4 % paraformaldehyde, and analyzed by confocal microscopy (laser scanning confocal microscope; Olympus FV1000, Japan).
Nanoparticle targeting in EGFR overexpression
Flow cytometry was used to quantify the targeting potential of the nanoparticles. Flow cytometry was performed using a FACScan Cytometer (BD FACSCalibur; BD Biosciences, USA) by counting 30,000 events, and the data were analyzed using FlowJo software. The experiments were performed as follows: nanoparticles were added at a concentration of 1 mg/10 6 cells and incubated for 4 h at 37 °C. After incubation, 5 × 10 6 cells were washed twice with 500 μL of PBS buffer by centrifugation (2000 rpm for 10 min), and a 250-μL cell suspension was obtained. Another 250 μL of 4 % paraformaldehyde was then added and analyzed by flow cytometry.
Direct labeling (Nordberg et al. 2007)
EGFR-BSA-PCL and BSA-PCL were labeled with 131 I (Beijing atomic Hi-tech Co., Ltd.) using the chloramine-T method. Approximately 100 µg of EGFR-BSA-PCL or BSA-PCL was diluted in PB to a total volume of 100 μL, and ~74 MBq 131 I was added. Chloramine-T (100 μL; 5 mg/mL in PB) was added. After 60 s of shaking and incubation, the reaction was stopped by adding 100 μL of sodium metabisulfite (5 mg/mL in PB). To separate labeled EGFR-BSA-PCL and BSA-PCL from low molecular weight compounds, a centrifuge tube (Amicon ® Pro Purification System, Merck Millipore) was used. The specific radioactivity was approximately 370-690 MBq/mg for 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL. The labeling rate of 131 I was approximately 50-85 %.
Competitive effect study in vitro (Du et al. 2013)
To further investigate the competitive effect of EGFR on the uptake of the nanoparticles, tumor cells were seeded in 24-well plates overnight and were incubated with 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL for 1 h; radioactivity was measured using a γ counter (LKB gamma 1261; LKB Instruments). Next, 500 μL rhEGF (0.2 ng/mL, Promega, USA) was added to these cells for 1 h, and then tumor cells were incubated with 131 I-EGFR-BSA-PCL for another 1 h. After incubation, cells were washed three times with PBS before radioactivity was measured.
Western blot analysis
For Western blot analysis, the PS 2A200 electrophoresis system (Amersham Biosciences, USA) was used. Membranes were incubated with EGFR (dilution 1:1000, sc-120, Abcam, USA) or β-actin (dilution 1:1000, TA-09, Novus Biologicals, USA) antibodies for 2 h at room temperature. The membranes were then incubated with secondary antibodies at room temperature for another 1 h and covered with Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, USA) at room temperature for 1 min and exposed to Fuji X-ray film in the darkroom. Prestained protein molecular weight standards (Spectra Multicolor Broad Range Protein Ladder, SM1841, Fermentas, Germany) were run in the same gels for molecular weight comparison and estimation of transfer efficiency.
Cell killing with 131 I and MTT assay (Chung et al. 2011)
To examine the effects of 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL on cell growth, tumor cells were seeded in 96-well plates at 1 × 10 4 cells per well overnight and were incubated with 131 I-EGFR-BSA-PCL or 131 I-BSA-PCL under different concentration doses for 4 h. All of the nanoparticles were then wiped off, and the cells were incubated for another 24 h. To examine whether radionuclide nanoparticles can kill tumor cells, the cells were extensively washed twice with PBS, and 20 μL of MTT reagent (5.0 mg/mL) [3-(4, 5 dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide; Sigma] was added to each well for 4 h. The amount of formazan blue compound indicates the number of living cells and was determined using a spectrophotometer (BioTek, ELX800, USA) at λ = 492 nm. To measure the time-dependent cellular uptake of 131 I-labeled nanoparticles, 1 × 10 5 cells per well were seeded in 96-well plates and cultured with 3.7 MBq/mL 131 I-EGFR-BSA-PCL, 131 I-BSA-PCL, or 131 I. The cells were washed, lysed with 0.3 M sodium hydroxide, and counted every 2 h for 4 h, every 4 h until 12 h, and then every 6 h until 24 h. Radioactivity was measured using a γ counter (LKB gamma 1261; LKB Instruments). All of the experiments were performed in triplicate.
Time
131 I could not be retained in non-thyroid cells, so these cells comprised the control group.
Animal model
Experimental animals were purchased from the Beijing Experimental Animal Center of Peking Union Medical, China. The generation of subcutaneous tumors was performed as follows: a 5 × 10 6 NCI-H1972 tumor cell suspension in 50 µL of DMEM was subcutaneously injected into the right shoulder of 4-week-old BALB/c female nude mice weighing 19-21 g. Mice were kept under specific pathogen-free conditions at the Laboratory Animal Center, Tianjin Medical University, China. The animal experiment guidelines were followed according to the regulations of Swiss veterinary law. The results were similar to those of the in vitro clonogenic assay in MDA-MB-231, MDA-MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, and A431 EGFR-overexpressing tumor cells. Therefore, NCI-H1972 cells were selected for animal testing. For the therapeutic experiments, all 20 mice were divided into four groups in terms of the 131 I-labeled EGFR-targeted nanoparticle 131 I-EGFR-BSA-PCL, the 131 I-labeled non-targeted nanoparticle 131 I-BSA-PCL, the EGFR-targeted nanoparticle EGFR-BSA-PCL, and the non-targeted nanoparticle BSA-PCL.
Tissue distribution of 131 I, 131 I-EGFR-BSA-PCL, and 131 I-BSA-PCL
The mice bearing human cancer were used for the biodistribution study at day 21 after tumor inoculation. The mice in each group were killed at 24 and 72 h post-injection with the respective drugs. The heart, spleen, liver, colon, and tumor samples were collected for weighing and for radioactivity measurements with a γ counter (LKB gamma 1261; LKB Instruments). Meanwhile, the remaining spleen, liver, and tumor tissues were collected to study the histopathology of each group. Data were expressed as each gram of tissue (% ID/g) (Li et al. 2004 ).
Radioiodine therapy study in mice
When the tumors reached a minimum size of 10 mm in diameter, 74 MBq (370 MBq/mL) 131 I-EGFR-BSA-PCL, 74 MBq (370 MBq/mL) 131 I-BSA-PCL, 1 mg (20 mg/mL) EGFR-BSA-PCL, or 1 mg (20 mg/mL) BSA-PCL was injected into the tumor. The tumor size was monitored prior to the administration of radioiodine and every 3 days thereafter by measuring three diameters with a sliding caliper and converting the diameter to the volume using the formula V = 4πabc/3. Control groups were followed to day 15 after injection and then killed due to excessive tumor burden by cervical dislocation under deep isoflurane sedation. The therapy groups were followed to day 35 after injection and were then killed.
Statistical analysis
All of the experiments were performed in triplicate unless otherwise indicated in vitro. Statistical analysis was conducted using SPSS software version 13.0. The results are presented as the mean ± SD. Statistical significance was tested using Student's t test or ANOVA.
Results
Size and morphology of BSA-PCL and EGFR-BSA-PCL
The size and morphology of the resulting BSA-PCL and EGFR-BSA-PCL were measured by a laser particle size analyzer and transmission electron microscopy (TEM). TEM analyses (insets of Fig. 1 ) of BSA-PCL and EGFR-BSA-PCL showed that the shape of the BSA carrier was retained after modification. They were both well-dispersed nanoparticles with a spherical shape. The DLS measurement showed the average diameter was approximately 130-180 nm and the polydispersity index (PDI) was 0.164, in agreement with the TEM result. The mean ζ potential of the obtained protein-based vesicle was also measured, with a value of −38.70 mV. The negative surface charge that resulted from the BSA shell could reduce undesired protein adsorption and provide good protection for the vesicle during circulation in the body. The diameter of nanoparticle EGFR-BSA-PCL was approximately 180 nm, the radius of BSA was 3.5 nm, the hydronamic radius of antibody C225 was 1.5 nm; so, the surface area of the nanoparticle was 101,736 nm 2 , and the cross-sectional area of C225 and BSA were 7.1 and 38.5 nm 2 , respectively. According to the ratio of BSA and C225 measured by HPLC, the amount of antibody per nanoparticle was estimated to be approximately 3800 antibody molecules per nanoparticle.
Internalization of EGFR-BSA-PCL and BSA-PCL
Confocal microscopy was used to evaluate the binding of EGFR-BSA-PCL and BSA-PCL to target tumor cells with high EGFR expression. We investigated their targeting abilities against different cancer cells. Figure 2 shows the confocal images of MDA-MB-231, MDA-MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, and A431 cancer cells incubated with EGFR-BSA-PCL and BSA-PCL. Immunofluorescence (Fig. 2) showed that EGFR-BSA-PCL was significantly internalized in EGFR-overexpressed tumor cells and exhibited strong green fluorescence. Compared with EGFR-BSA-PCL, BSA-PCL could also bind to cells, but tumor cell retention was minimal and the binding green fluorescence was weak. This result suggests that the targeting ability of nanoparticles was enhanced via modification with anti-EGFR antibody.
Flow cytometry of nanoparticle binding and cellular uptake
Fluorescence-activated cell-sorting analyses revealed results consistent with those observed in confocal microscopy analyses, showing a significant uptake of EGFR-BSA-PCL. As shown in Fig. 3 , rapid and efficient binding of EGFR-BSA-PCL to EGFR-overexpressing target cell lines was demonstrated. The binding and uptake of EGFR-BSA-PCL were higher than those of non-targeted nanoparticles in MDA-MB-231, MDA-MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, and A431 cell lines (p < 0.05). This finding implies that EGFR-BSA-PCL had a special binding efficiency with tumor cells expressing EGFR.
Competitive effect study in vitro
After rhEGF was added to these cells for 1 h, radioiodide uptake in the rhEGF + 131 I-EGFR-BSA-PCL group was lower than the 131 I-EGFR-BSA-PCL group. The results showed that rhEGF bound to EGFR receptors on the surfaces of tumor cells, C225-mediated endocytosis of nanoparticles was restrained, the endocytosis of 131 I-EGFR-BSA-PCL was also restrained, and radioiodide uptake was depressed in EGFR-overexpressing tumor cells (Fig. 4) .
Targeted cell killing with 131 I
The EGFR expression was assayed by Western blot in I to evaluate the efficiency and specificity of targeted cell killing. In recent studies, a similar treatment with the antihuman EGFR antibody C225 showed no cytotoxicity using the MTT assay (Mamot et al. 2003) . EGFR-BSA-PCL and BSA-PCL also showed no cytotoxicity using the MTT assay (Liu et al. 2014) . Furthermore, nanoparticles containing C225-Fab, but lacking an encapsulated drug, similarly showed no cytotoxicity under these MTT assay conditions (Mamot et al. 2003) . Thus, (Fig. 6a) , 0.34 (Fig. 6b) , and 0.04 MBq/mL (Fig. 6c) , respectively, whereas those of 131 I-BSA-PCL were 0.71 (Fig. 6a) , 0.39 (Fig. 4b) , and 0.25 MBq/mL (Fig. 6c) , respectively. Meanwhile, the IC50 values of 131 I-EGFR-BSA-PCL in NSCLC cell lines NCI-H292 and NCI-H1972 were 0.70 (Fig. 6e) and 0.70 MBq/mL (Fig. 6f) , respectively, whereas those of 131 I-BSA-PCL were 1.8 (Fig. 6e ) and 3.26 MBq/mL (Fig. 6f) , respectively. The IC50 values of 131 I-EGFR-BSA-PCL in the colorectal cancer cell line LS180 and squamous cell carcinoma cell line A431 were 1.32 (Fig. 6d) and 0.03 MBq/mL (Fig. 6g) , respectively, (Fig. 6d ) and 0.32 MBq/mL (Fig. 6g) , respectively. The survival rates of tumor cells not incubated with 131 I that were only incubated with 131 I were similar because non-thyroid tumor cells could not uptake 131 I; thus, 131 I retention was too short to kill the cells, as shown in Fig. 6 .
Time-dependent cellular uptake
To determine the iodide uptake of 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL, 131 I-timed activity measurements were obtained in MDA-MB-231, MDA-MB-453, MDA-MB-468, LS180, NCI-H1975, NCI-H292, and A431 tumor Figure 8a shows the average tumor volume progression for the two 131 I-nanoparticle therapy groups and the two corresponding unlabeled nanoparticle control groups. Injection on day 3 was used as the initial reference due to the significant tumor swelling on day 1 and day 2. On day 35, the average tumor volumes of the 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL groups were 329.7 ± 135.2 and 365.6 ± 113.8 %, respectively. On day 15, the average tumor volumes of the 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL groups were 180.9 ± 107.5 and 205.7 ± 25.2 %, respectively, indicating slow growth. In comparison, tumors in the EGFR-BSA-PCL and BSA-PCL nanoparticle control groups showed rapid growth, with tumor volumes of 272.7 ± 138.1 and 312.2 ± 182.8 %, respectively, at day 15.
Radioiodine therapy study in mice
The tissue distribution of 131 I-EGFR-BSA-PCL in nude mice was measured by γ counts in Fig. 8b .
131 I-EGFR-BSA-PCL was markedly absorbed by tumor tissues. Among the non-tumor tissues, 131 I-EGFR-BSA-PCL was mostly accumulated in the liver and spleen. The levels of 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL in tumor tissues were significantly higher than in the other two groups at 24 and 72 h after treatment.
Discussion
Tumor-targeting therapy has overcome the lack of specificity of traditional therapeutic agents. Liposomes, which are spherical vesicles formed by lipid bilayers, have been widely investigated as carriers of tumor-targeting therapeutic agents. Some specific ligands have been conjugated to nanoparticles that serve as carriers for a therapeutic agent and have been used to increase the specific toxicity of tumor therapy by specific delivery to target cells, including folic acid (Pinhassi et al. 2010 ), Arg-Gly-Asp peptides (Su et al. 2012) , vitamins (Chen et al. 2010) , aptamers (Neff et al. 2011) , and antibodies (Mamot et al. 2003) . In particular, immunoliposomes directed against EGFR ligands can increase the targeting therapeutic efficacy in vivo and may be of important clinical significance as a novel treatment for cancer (Mamot et al. 2005) . Previous studies also revealed that rapid internalization of the receptor ligand can occur upon binding to EGFR (Brand et al. 2011) and that PEGylation at the surface of nanoparticles can increase the half-life of the nanoparticles in vivo (Gupta and Torchilin 2007) .
The currently available targeting radiotherapies (e.g., radionuclide-labeled monoclonal antibodies and peptides) have some limitations in targeted radionuclide therapy, such as the insufficient delivery of radionuclides to the tumor tissue because of the relatively low and heterogeneous expression of receptors on tumor cells and the dose-limiting toxicities to normal tissues. Innovative radionuclide nanoparticle delivery systems can improve and enhance the targeted transport of cytotoxic drugs or radionuclides to tumor lesions, maximize the therapeutic index, and minimize the toxicity. Five approaches are generally used for labeling or encapsulating radionuclides on nanoparticles: labeling nanocarriers by encapsulation during preparation, nanocarrier surface labeling after preparation, nanocarrier surface labeling of bioconjugates after preparation, incorporation into the lipid bilayer after preparation, and afterloading of the aqueous phase of nanocarriers after preparation (Ting et al. 2010) . In the present research, we used the technique of nanocarrier surface labeling after preparation. The use of active targeting radionuclide nanoparticles in internal radiotherapy has been successfully employed to image and treat tumor models preclinically. These radionuclide nanoparticles include human atherosclerotic plaque-specific peptide-1-targeted 111 In-labeled liposomes (Yang et al. 2012) , monoclonal antinuclear autoantibody 2C5 (mAb 2C5) targeting 111 In-immunoliposome for lung carcinoma (Elbayoumi et al. 2007 ), α v β 3 -integrintargeted 111 In perfluorocarbon nanoparticles for targeted tumor imaging (Hu et al. 2007) , rituximab targeting 111 In carbon nanotubes for targeted tumor imaging (McDevitt et al. 2007) , RGD-or VEGF-targeted 64 Cu quantum dots or iron oxide for PET/NIRF and PET/MRI imaging Lee et al. 2008) , EGFR-targeted 99m Tc-chelated quantum dots for breast cancer imaging and therapy (Jung et al. 2011) , RGD-targeted 125 I-labeled gold nanoparticles for tumor imaging (Kim et al. 2011 ), HER2-targeted nanoparticles loaded with an 125 I-labeled DNA intercalator (Fondell et al. 2011 ), anti-prostate-specific membrane antigen nanoparticles loaded with 225 Ac for potential targeted anti-vascular α-particle therapy (Bandekar et al. 2014) , 76 Br-labeled RGD-directed-dendritic nanoprobes for PET imaging (Almutairi et al. 2009 ), and integrin antagonist or anti-Flk-1 antibody-coated 90 Y-labeled nanoparticles (Li et al. 2004) .
Radionuclide nanoparticles have other advantages; they do not require a homogeneous distribution because emitting radionuclides (such as 131 I) can provide remote killing of cancer cells and they can tolerate imaging during treatment. For targeted radionuclide internal radiotherapy applications, high energy and low energy between 0.1 and 2.2 MeV of β-emitters are ideal radioisotopes for the treatment of small-to-large clusters of tumor cells; the maximum tissue penetration range (1-10 mm) and cross-fire effects of β-particles can kill tumor cells in close proximity to the neovasculature (Carlsson et al. 2003; Milenic et al. 2004; Mitra et al. 2006) . Several β-emitting radioisotopes, such as 131 I, 90 Y, 186 Re, and 177 Lu, have been used to treat cancer for many years (Ting et al. 2010) . Iodine-131 is an ideal radionuclide for therapeutic use because of its maximum β emission of 0.64 MeV with a long physical halflife of 8 days and a γ emission of 364 keV for imaging purposes in the current study. Moreover, 131 I radioiodine therapy for differentiated thyroid carcinomas has been used for numerous years. Given the bystander effect of radiation therapy, radioiodine may kill not only the tumor cells with uptake of radionuclide nanoparticles but also adjacent tumor cells. Although 131 I-labeled anti-EGFR antibodytargeted radiotherapy has been reported, EGFR-targeted 131 I-labeled nanoparticle radiotherapy in tumor cell lines has not yet been reported.
In the present paper, we describe for the first time a detailed study showing that EGFR-targeted 131 I-labeled nanoparticles allowed the evaluation of tumor targeting and therapeutic efficacy in vitro. Nanoparticles were constructed with anti-EGFR mAb fragments (C225) to deliver drugs selectively to tumor cells with EGFR overexpression. Using flow cytometry and confocal microscopy analysis, the EGFR-targeted nanoparticle EGFR-BSA-PCL showed specific binding and internalization in the EGFR-overexpressing cell lines MDA-MB-468, MDA-MB-453, and MDA-MB-468 (breast cancer); NCI-H292 and NCI-H1975 (lung cancer); LS180 (colorectal cancer); and A431 (squamous cell carcinoma). Using confocal microscopy, the selectivity for tumor cells was confirmed by revealing strong and specific binding of EGFR-BSA-PCL to targeted cancer cells. Flow cytometry revealed results consistent with those observed in fluorescent microscopy analyses, showing a significant uptake of EGFR-BSA-PCL. Moreover, the total cellular uptake of EGFR-BSA-PCL in these cells was higher than that of non-targeted nanoparticles in MDA-MB-231, MDA-MB-453, MDA-MB-468, NCI-H292, NCI-H1975, LS180, and A431 cell lines (p < 0.05). This finding indicates that the targeting ability of EGFR-BSA-PCL to tumor cells was enhanced via EGFR modification, resulting in EGFR receptor-mediated endocytosis.
In MTT assays, 131 I-EGFR-BSA-PCL was found to selectively kill EGFR-overexpressed tumor cells in a dosedependent manner after incubation with radionuclide nanoparticles for 4 h. All of the nanoparticles were wiped off and the cells were incubated for another 24 h. The value of 131 I-EGFR-BSA-PCL IC50 in EGFR-overexpressed tumor cells was lower than that of 131 I-BSA-PCL. The cytotoxicity of 131 I-EGFR-BSA-PCL was found to be dependent on the radiation dose and was higher than that with the non-targeted nanoparticle 131 I-BSA-PCL. The survival rates of 131 I-EGFR-BSA-PCL were lower than those of 131 I-BSA-PCL in all tumor cells. Notably, no toxicity was observed when EGFR low expressing cells were incubated with the same nanoparticle. The toxic effects of EGFR-BSA-PCL and BSA-PCL were very low, as previously described against the glioma cell line U87 (Liu et al. 2014 ).
In the time-dependent cellular uptake experiments of 131 I-labeled nanoparticle nanoparticles, the data showed that 131 I-EGFR-BSA-PCL exhibited increased 131 I accumulation, and the intracellular 131 I retention of 131 I-EGFR-BSA-PCL was higher than that of 131 I-BSA-PCL because the EGFR-targeted nanoparticles demonstrated superior cellular binding and enhanced cellular uptake. The cells incubated with 131 I-BSA-PCL also showed intracellular retention of iodine, but the retention was lower in 131 I-BSA-PCL than that in 131 I-EGFR-BSA-PCL. PEGylation at the surface of nanoparticles has been well documented to increase the half-life of the nanoparticles (Gupta and Torchilin 2007) . Thus, the cell-associated 131 I activity after 24 h was still very high, at almost 79-84 % in all seven cell lines. The 131 I-labeled nanoparticles showed excellent slow-release effects and better-targeted cell killing with 131 I. These nanoparticles may be used in preparations for future nude mice studies in vivo.
The high loco-regional retention rate led to good therapeutic results in the radioiodine therapy study in mice. In this study, we were able to deliver 74 MBq of radiation for the 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL 1 3 nanoparticle groups. The two control groups showed no response regarding the unlabeled nanoparticles and showed relentless tumor enlargement. The average tumor volumes of the 131 I-EGFR-BSA-PCL group was lower than those of the 131 I-BSA-PCL groups in a mid-stage experiment because EGFR-targeted nanoparticles increased tumor cell binding and uptake and led to stronger cell killing with 131 I. However, the effect of radioiodine therapy became weaker with extended time, so the average tumor volumes of the 131 I-EGFR-BSA-PCL group were similar at the end of the experiment. The data showed that 131 I therapy could retard tumor growth in a mid-stage experiment. The difference between the tumor size of the 131 I-EGFR-BSA-PCL and 131 I-BSA-PCL nanoparticle groups was most likely due to EGFR-targeted liposomes increasing tumor cellular binding and uptake. Although intravenous injection of nanoparticles would be simpler and better than intratumoral injection in the radioiodine therapy study in mice, the data for intravenous injection showed that the nanoparticles were mostly retained in the liver and ) at 24 h after therapy, respectively spleen, secondary to the tumor; thus, the treatment effect of 131 I-labeled nanoparticles was poor in vivo. In the in vivo radioiodine therapy study, EGFR-targeted 131 I-labeled nanoparticles had a favorable biological half-life and retarded tumor growth to some extent, but the effect of radioiodine therapy was decreased with time. This may be because 131 I did not have enough radiation energy; thus, more powerful radionuclides instead of 131 I in EGFR-targeted nuclide nanoparticles could be used in future research.
In conclusion, EGFR-BSA-PCL exhibited superior cellular binding and enhanced cellular uptake compared with the control BSA-PCL. Furthermore, 131 I-EGFR-BSA-PCL achieved a favorable intracellular retention of 131 I, excellent targeted cell killing, and slow-release effects, and it suppressed the cancer cell growth caused by EGFR overexpression. The radionuclide-targeted anti-EGFR nanoparticle 131 I-EGFR-BSA-PCL is a good candidate for targeted drug delivery purposes in EGFR-targeted therapeutic approaches for 131 I radioiodine treatment for breast cancer, lung cancer, colorectal cancer, and squamous cell carcinoma cell lines.
